<div id="readability-page-1">08:12 AM EST, 12/29/2025 (MT Newswires) -- Zevra Therapeutics ( ZVRA ) said Monday that it has signed an exclusive, expanded access distribution agreement with Irish pharmaceutical services provider Uniphar.The agreement will enable reimbursed named patient supply of Miplyffa, Zevra's treatment for Niemann-Pick disease type C, in certain territories outside of Europe, the company said.Miplyffa, or arimoclomol, is approved in the US and under review by the European Medicines Agency, the company said.Shares of Zevra were up more than 1% in recent premarket activity Monday. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</div>

ZVRA

Zevra Therapeutics 已与 Uniphar 签署了 Miplyffa 的独家分销协议，该药物用于治疗 C 型尼曼 - 匹克病，允许在欧洲以外的特定地区进行报销供应。Miplyffa 在美国已获得批准，并正在欧洲审核中。Zevra 的股票在盘前交易中上涨超过 1%

Zevra Therapeutics 与 Uniphar 签署了扩展的 Miplyffa 分销协议